ArticleCurrent oncology (Toronto, Ont.)2009

The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

J Lemieux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.